KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.

Kim Papp, Jacek C Szepietowski, Leon Kircik, Darryl Toth, Lawrence F Eichenfield, Seth B Forman, Michael E Kuligowski, Howard Kallender, Kang Sun, Haobo Ren, Eric L Simpson

J Am Acad Dermatol 88(5) 1008-1016

PMID36574595
PMCID-
DOI10.1016/j.jaad.2022.09.060
发表日期2022-12-27
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Ruxolitinib cream demonstrated safety and efficacy over 8 weeks in 2 double-blind phase 3 atopic dermatitis studies (NCT03745638/NCT03745651). OBJECTIVE: To evaluate long-term safety (LTS) and disease control with ruxolitinib cream. METHODS: Patients initially randomized to twice-daily 0.75%/1.5% ruxolitinib cream maintained their regimen during the 44-week LTS period (as-needed treatment). Patients on vehicle were rerandomized (1:1) at week 8 to either ruxolitinib cream strength. Safety and disease control (Investigator's Global Assessment score 0/1 and affected body surface area) were assessed. RESULTS: Over 52 weeks, adverse events were reported in 67.4%/62.6%/53.5%/57.6% of patients in 0.75%/1.5% ruxolitinib cream/vehicle to 0.75% ruxolitinib cream/vehicle to 1.5% ruxolitinib cream groups (n = 426/446/101/99). Most common adverse events were upper respiratory tract infection (10.3%/11.4%/5.9%/7.1%) and nasopharyngitis (8.9%/9.9%/7.9%/14.1%). Most adverse events were considered unrelated to treatment. Application site reactions were infrequent (3.8%/1.8%/1.0%/1.0%). Disease control was achieved throughout the LTS; 74.1% to 77.8% of patients had Investigator's Global Assessment 0/1 at week 52, and mean affected body surface area was low (1.4%-1.8%). LIMITATIONS: LTS had no control treatment. CONCLUSION: During 44 weeks of as-needed treatment, ruxolitinib cream demonstrated effective disease control and tolerability; low ruxolitinib plasma concentrations alongside safety findings reflecting known risk factors suggest physiologically meaningful systemic Janus kinase inhibition is highly unlikely.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。